Chugai Pharmaceutical Co Ltd ADR (CHGCY)

OTC Markets
Currency in USD
25.91
-0.38(-1.45%)
Closed·
CHGCY Scorecard
Full Analysis
Has raised its dividend for 4 consecutive years
CHGCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.3026.92
52 wk Range
15.4431.26
Key Statistics
Edit
Prev. Close
26.29
Open
25.3
Day's Range
25.3-26.92
52 wk Range
15.44-31.26
Volume
63.56K
Average Volume (3m)
175.63K
1-Year Change
65.56%
Book Value / Share
7.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CHGCY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

Chugai Pharma ADR Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Employees
5026

Compare CHGCY to Peers and Sector

Metrics to compare
CHGCY
Peers
Sector
Relationship
P/E Ratio
29.9x18.3x−0.4x
PEG Ratio
1.170.100.00
Price/Book
6.4x1.4x2.6x
Price / LTM Sales
10.0x1.5x3.1x
Upside (Analyst Target)
-15.0%51.1%
Fair Value Upside
Unlock24.4%8.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 249.26%
Dividend Yield
-
Industry Median 1.73%
Annualised payout
-
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Mar 27, 2025
EPS / Forecast
55.62 / --
Revenue / Forecast
302.07B / --
EPS Revisions
Last 90 days

CHGCY Income Statement

FAQ

What Is the Chugai Pharma ADR (CHGCY) Stock Price Today?

The Chugai Pharma ADR stock price today is 25.91.

What Stock Exchange Does Chugai Pharma ADR Trade On?

Chugai Pharma ADR is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Chugai Pharma ADR?

The stock symbol for Chugai Pharma ADR is "CHGCY."

What Is the Chugai Pharma ADR Market Cap?

As of today, Chugai Pharma ADR market cap is 85.16B.

What Is Chugai Pharma ADR's Earnings Per Share (TTM)?

The Chugai Pharma ADR EPS (TTM) is 249.26.

From a Technical Analysis Perspective, Is CHGCY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Chugai Pharma ADR Stock Split?

Chugai Pharma ADR has split 1 times.

How Many Employees Does Chugai Pharma ADR Have?

Chugai Pharma ADR has 5026 employees.

What is the current trading status of Chugai Pharma ADR (CHGCY)?

As of 15 Jun 2025, Chugai Pharma ADR (CHGCY) is trading at a price of 25.91, with a previous close of 26.29. The stock has fluctuated within a day range of 25.30 to 26.92, while its 52-week range spans from 15.44 to 31.26.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.